ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
40.99
0.91%
US Tech 100
21,179.20
1.25%
S&P 500
6,060.45
0.57%
US Dollar vs CAD
1.43175
0.15%
Bitcoin
97,126.20
0.66%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Eupraxia Pharmaceuticals Inc (EPRX)

  7. Eupraxia Pharmaceuticals Inc (EPRX) News

EPRX

Eupraxia Pharmaceuticals (EPRX)

Eupraxia Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:EPRX
DateTimeSourceHeadlineSymbolCompany
11/20/20247:57AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EPRXEupraxia Pharmaceuticals Inc
11/20/20246:00AMPR Newswire (US)Eupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six MonthsNASDAQ:EPRXEupraxia Pharmaceuticals Inc
11/20/20246:00AMPR Newswire (Canada)Eupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six MonthsNASDAQ:EPRXEupraxia Pharmaceuticals Inc
11/14/20244:00PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EPRXEupraxia Pharmaceuticals Inc
11/14/20244:00PMPR Newswire (US)Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual MeetingNASDAQ:EPRXEupraxia Pharmaceuticals Inc
11/14/20244:00PMPR Newswire (Canada)Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual MeetingNASDAQ:EPRXEupraxia Pharmaceuticals Inc
11/13/20244:01PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EPRXEupraxia Pharmaceuticals Inc
11/13/20244:00PMPR Newswire (Canada)Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024NASDAQ:EPRXEupraxia Pharmaceuticals Inc
11/13/20244:00PMPR Newswire (US)Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024NASDAQ:EPRXEupraxia Pharmaceuticals Inc
11/12/20244:56PMPR Newswire (US)Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic EsophagitisNASDAQ:EPRXEupraxia Pharmaceuticals Inc
11/12/20244:56PMPR Newswire (Canada)Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic EsophagitisNASDAQ:EPRXEupraxia Pharmaceuticals Inc
11/08/202410:49AMEdgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:EPRXEupraxia Pharmaceuticals Inc
11/07/20244:17PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EPRXEupraxia Pharmaceuticals Inc
11/07/20244:00PMPR Newswire (US)Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial ResultsNASDAQ:EPRXEupraxia Pharmaceuticals Inc
11/07/20244:00PMPR Newswire (Canada)Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial ResultsNASDAQ:EPRXEupraxia Pharmaceuticals Inc
11/07/20243:10PMEdgar (US Regulatory)Form SC 13D - General Statement of Acquisition of Beneficial OwnershipNASDAQ:EPRXEupraxia Pharmaceuticals Inc
10/31/20246:36PMPR Newswire (US)Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 MillionNASDAQ:EPRXEupraxia Pharmaceuticals Inc
10/31/20246:36PMPR Newswire (Canada)Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 MillionNASDAQ:EPRXEupraxia Pharmaceuticals Inc
10/28/20246:02AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EPRXEupraxia Pharmaceuticals Inc
10/28/20246:00AMPR Newswire (Canada)Eupraxia Pharmaceuticals to Present at American College of Gastroenterology Annual Scientific Meeting 2024NASDAQ:EPRXEupraxia Pharmaceuticals Inc
10/28/20246:00AMPR Newswire (US)Eupraxia Pharmaceuticals to Present at American College of Gastroenterology Annual Scientific Meeting 2024NASDAQ:EPRXEupraxia Pharmaceuticals Inc
10/15/20247:06AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EPRXEupraxia Pharmaceuticals Inc
10/15/20246:00AMPR Newswire (Canada)Lancet Rheumatology Publishes Phase 2b Data on Eupraxia Pharmaceuticals' EP-104IAR for the Treatment of Knee OsteoarthritisNASDAQ:EPRXEupraxia Pharmaceuticals Inc
10/15/20246:00AMPR Newswire (US)Lancet Rheumatology Publishes Phase 2b Data on Eupraxia Pharmaceuticals' EP-104IAR for the Treatment of Knee OsteoarthritisNASDAQ:EPRXEupraxia Pharmaceuticals Inc
10/10/20246:01AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EPRXEupraxia Pharmaceuticals Inc
10/10/20246:00AMPR Newswire (Canada)Eupraxia Pharmaceuticals to Present at United European Gastroenterology Week 2024NASDAQ:EPRXEupraxia Pharmaceuticals Inc
10/10/20246:00AMPR Newswire (US)Eupraxia Pharmaceuticals to Present at United European Gastroenterology Week 2024NASDAQ:EPRXEupraxia Pharmaceuticals Inc
10/02/20244:07PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EPRXEupraxia Pharmaceuticals Inc
10/02/20244:01PMPR Newswire (Canada)Eupraxia Pharmaceuticals Strengthens Senior Management TeamNASDAQ:EPRXEupraxia Pharmaceuticals Inc
10/02/20244:01PMPR Newswire (US)Eupraxia Pharmaceuticals Strengthens Senior Management TeamNASDAQ:EPRXEupraxia Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:EPRX

Your Recent History

NASDAQ
SMFL
Smart for Life
BIT
S29352
Societe Generale Effekten
BIT
P1WSS9
NLBNPIT1WSS9 20250620 33...
BIT
UC6Y6U
Unicredit Bank
BIT
XNJP
Xtrackers Japan Net Zero...
AQSE
XMED.GB
Deutsche Bank Luxembourg
AQSE
FOUR.GB
4imprint
BIT
P1RLH7
BNP Paribas Issuance
BIT
F38943
Vontobel Financial Produ...
BIT
P1QUN8
BNP Paribas Issuance
BIT
P1SD98
BNP Paribas Issuance
BIT
S29785
Societe Generale Effekten
BIT
A09773
Aldburg Public
BIT
P1M230
BNP Paribas Issuance
BIT
UB22HN
UniCredit Bank
BIT
XJSE
Exchange Traded Fund X J...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads